Otros idiomas Alphamab Oncology

Acciones

9966

KYG0330A1013

Mercado cerrado - Hong Kong S.E. Otros sitios de cotización 10:08:20 26/04/2024			Varia. Cinco días.	Varia. 1 de enero.
4,67 ^HKD	+4,94 %		+14,74 %	-29,67 %

10/04	Alphamab Oncology presenta los resultados del ensayo clínico de fase I en la reunión anual de la AACR de 2024	MT
10/04	Alphamab Oncology presentó en la Aacr los resultados de escalada de dosis de Jskn003 en pacientes con tumores sólidos avanzados/metastásicos	CI

Otros idiomas

Desbloquee todas las noticias sobre todas las empresas: ¡No vuelvas a perderse una oportunidad de inversión rentable!

Inscripción 100% Gratuita

Alphamab Oncology Presents Phase-I Clinical Trial Results at 2024 AACR Annual Meeting	10/04
Alphamab Oncology Presented the Dose-Escalation Results from Jskn003 in Patients with Advanced/Metastatic Solid Tumors At Aacr	10/04
Alphamab Oncology Announces Updates on Results of a Phase I Clinical Trial of JSKN003 for the Treatment of HER2-Expressing Advanced Solid Tumors for Presentation at 2024 AACR Annual Meeting	10/04
Alphamab Oncology Unit Renews Service Provision Contract, Annual Limits	04/04
Jiangsu Alphamab Biopharmaceuticals Co., Ltd. and Suzhou Alphamab Co., Ltd. Announces Renewal of the Lease Agreement	28/03
Alphamab Oncology Reports Earnings Results for the Full Year Ended December 31, 2023	28/03
Alphamab Oncology Announces the First Patient Dosed in Australia in the Clinical Study of Subcutaneous Formulation JSKN033	26/03
Alphamab Oncology Announces Results of Phase II Clinical Study of Kn046 Plus Chemotherapy as First-Line Treatment for Metastatic Nsclc Were Published in Cell Reports Medicine	22/03
Alphamab Oncology Announces Results of Phase II Clinical Study of KN046 in Combination with Nab-paclitaxel in TNBC were Published in Nature Communications	07/02
Alphamab Oncology and 3Dmedicines Enters into A Licensing Agreement with Glenmark for KN035	25/01
Alphamab Oncology Unit, 3D Medicines Grants Glenmark Unit License to Commercialize Sarcoma Injectable	25/01
Alphamab to Proceed With Australian Trials of Anti-Tumor Medication	08/12
Alphamab Oncology Announces Phase I/II Clinical Trial of Jskn033 Independently Developed by Group for the Treatment of Human Epidermal Growth Factor Receptor	08/12
Amoytop Biotech Signs Exclusive License Deal for Liver Disease Drug With Alphamab Unit	07/12
Alphamab Oncology Presents Research Data on Breast Cancer Treatment in US Meet; Shares Slip 3%	07/12
Alphamab Oncology Announces First Patient Dosed in Phase Iii Study of Jskn003 for the Treatment of Advanced Her2-Low Breast Cancer	04/12
Alphamab Logs Upbeat Results From Anti-Tumor Drug's Australian Trials	16/11
Alphamab Oncology Announces Preliminary Results of a Phase I Clinical Trial of JSKN003 in Australia for the Treatment of Her2-Expressing Advanced Solid Tumors	16/11
Alphamab Oncology Receives Recommendation to Continue Clinical Study for Anti-Tumor Drug	15/11
Alphamab Unaware of Reasons for Share Price Drop; Stock Tanks 21%	14/11

No hay resultados para esta búsqueda

Todas Recomendaciones analistas Eventos destacados Insiders Transcripts Comunicados Publs. oficiales Otros idiomas Ideas de trading Artículos de MarketScreener Estrategias MarketScreener

Otros idiomas Alphamab Oncology

Acciones

9966

KYG0330A1013

Otros idiomas

Filtros